Balixafortide (TFA)
Balixafortide TFA (POL6326 TFA) is a potent, selective, well-tolerated peptidic CXCR4 antagonist with an IC50 CXCR4 than a large panel of receptors including CXCR7. Balixafortide TFA blocks β-arrestin recruitment and calcium flux with IC50s [1][2].
Product Specifications
Product Name Alternative
POL6326 (TFA)
UNSPSC
12352209
Target
Arrestin; CXCR
Type
Peptides
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/balixafortide-tfa.html
Purity
99.89
Solubility
DMSO : 100 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)
Smiles
O=C(C(F)(F)F)O.O=C1[C@]2([H])N(CCC2)C([C@@H](NC([C@@H](NC([C@@H](NC([C@@]3([H])NC([C@@H](NC([C@@H](NC([C@@H](NC([C@]4([H])N(CCC4)C([C@@H](NC([C@@H](NC([C@@](CSSC3)([H])NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@]5([H])N1CCC5)=O)CC6=CC=C(C=C6)O)=O)CC7=CN=CN7)=O)C)=O)=O)CO)=O)C)=O)=O)CCN)=O)CCCNC(N)=N)=O)CC8=CC=C(C=C8)O)=O)=O)CC9=CC=C(C=C9)O)=O)CCC(N)=O)=O)CCCCN)=O
Molecular Formula
C86H119F3N24O23S2
Molecular Weight
1978.16
References & Citations
[1]Zimmermann J, et al. Anti-tumor cell activity and in vitro profile of the next generation CXCR4 antagonist Balixafortide. Ann Oncol. 2018 Oct;29 Suppl 8:viii103.|[2]Karpova D, et al. Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers-results of a dose escalation trial. J Transl Med. 2017 Jan 3;15 (1) :2.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture and light)
Scientific Category
Peptides
Clinical Information
Phase 3
Isoform
CXCR4
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNCB0009-100 1x 100 µL
MART-1 / Melan-A (M2-7C10), Biotin conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
